Literature DB >> 793608

Leukaemogenic action of phorbol in intact and thymectomized mice of different strains.

V Armuth.   

Abstract

Phorbol, the unesterified parent alcohol of the skin promoter TPA, was administered i.p., twice weekly, throughout the lifetime of mice of 7 inbred strains: males and females of AKR/J, C3Heb and BALB/c, and females of SJL/J, DBA/2, SWR and C57BL. A striking difference in strain response was observed, with a pronounced leukaemogenic effect in SWR, a signficiant shortening of the latent period for spontaneous reticulum cell sarcomas (RCNB) in SJL/J, and no demonstrable effect in the other strains. When mice of 3 of the above-mentioned strains (SWR, SJL/J and AKR/J) were thymectomized prior to the beginning of phorbol treatment, different patterns of response were again observed. Thymectomy did not influence the leukaemia incidence in SWR mice, slightly inhibited RCNB development in SJL/J mice and converted phorbol into a leukaemogenic agent for AKR/J mice.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 793608      PMCID: PMC2025214          DOI: 10.1038/bjc.1976.206

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Urethan induction of thymic lymphoma in C57bl mice.

Authors:  R G DOELL; W H CARNES
Journal:  Nature       Date:  1962-05-12       Impact factor: 49.962

2.  Normal and pathologic anatomy of the reticular tissue in laboratory mice, with a classification and discussion of neoplasms.

Authors:  T B DUNN
Journal:  J Natl Cancer Inst       Date:  1954-06       Impact factor: 13.506

3.  Antitumour activity in vitro dependent on immune B lymphocytes.

Authors:  E W Lamon; H Wigzell; B Andersson; E Klein
Journal:  Nat New Biol       Date:  1973-08-15

4.  Systemic promoting action of phorbol in liver and lung carcinogenesis in AKR mice.

Authors:  V Armuth; I Berenblum
Journal:  Cancer Res       Date:  1972-10       Impact factor: 12.701

5.  Thymus and bone marrow derived lymphatic leukaemia in mice.

Authors:  N Haran-Chera; A Peled
Journal:  Nature       Date:  1973-02-09       Impact factor: 49.962

6.  On a possible cocarcinogenic and immunosuppressive activity of phorbol in AKR-mice.

Authors:  D Gericke; W Kovac; E Hecker
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1974

7.  Promotion of mammary carcinogenesis and leukemogenic action by phorbol in virgin female Wistar rats.

Authors:  V Armuth; I Berenblum
Journal:  Cancer Res       Date:  1974-10       Impact factor: 12.701

Review 8.  Tumor-promoting agents in two-stage carcinogenesis.

Authors:  B L Van Duuren
Journal:  Prog Exp Tumor Res       Date:  1969

9.  Phorbol as a possible systemic promoting agent for skin carcinogenesis.

Authors:  V Armuth; I Berenblum
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-01-02

10.  Studies on the mechanisms of chemical leukaemogenesis.

Authors:  T M Dexter; R Schofield; L G Lajtha; M Moore
Journal:  Br J Cancer       Date:  1974-10       Impact factor: 7.640

View more
  4 in total

1.  Sudden outbreak of a leukemia-like lesion in female CBA mice after repeated injections of 5-azacytidine.

Authors:  A Luz; A B Murray
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

2.  The effect of tumor-promoting phorbol diesters on terminal differentiation of cells in culture.

Authors:  J Abrahm; G Rovera
Journal:  Mol Cell Biochem       Date:  1980-08-16       Impact factor: 3.396

3.  Systemic promoting action and leukemogenesis in SWR mice by phorbol and structurally related polyfunctional diterpenes.

Authors:  V Armuth; I Berenblum; W Adolf; H J Opferkuch; R Schmidt; B Sorg; E Hecker
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

4.  A carcinogenic potency database of the standardized results of animal bioassays.

Authors:  L S Gold; C B Sawyer; R Magaw; G M Backman; M de Veciana; R Levinson; N K Hooper; W R Havender; L Bernstein; R Peto
Journal:  Environ Health Perspect       Date:  1984-12       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.